Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (291-300 of 1,211) with videos related to

Pageof 122
Sort By:
Journal of the American College of Cardiology|October 9, 2020
Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art ReviewBahar Behrouzi, Maria Viviana Araujo Campoverde, Kyle Liang, et al.
European Journal of Heart Failure|January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-PreservedJennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
The New England Journal of Medicine|January 1, 2015
The amyloidogenic V122I transthyretin variant in elderly black AmericansC Cristina Quarta, Joel N Buxbaum, Amil M Shah, et al.
JACC. Heart Failure|March 16, 2020
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position PaperNasrien E Ibrahim, John C Burnett, Javed Butler, et al.
Diabetes Research and Clinical Practice|November 21, 2022
Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) studyMagnus O Wijkman, Brian L Claggett, Marcus V B Malachias, et al.
JACC. Heart Failure|December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health StatusSean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
JAMA Cardiology|October 10, 2019
Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities StudyStephen Y Wang, Andy S L Tan, Brian Claggett, et al.
European Journal of Heart Failure|September 19, 2018
The frailty syndrome and outcomes in the TOPCAT trialNatalie A Sanders, Mark A Supiano, Eldrin F Lewis, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|December 2, 2006
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic studyJens Jakob Thune, Lars Køber, Marc A Pfeffer, et al.
Pageof 122

Showing results (291-300 of 1,211) with videos related to

Sort By:
Pageof 122
Journal of the American College of Cardiology|October 9, 2020
Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art ReviewBahar Behrouzi, Maria Viviana Araujo Campoverde, Kyle Liang, et al.
European Journal of Heart Failure|January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-PreservedJennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
The New England Journal of Medicine|January 1, 2015
The amyloidogenic V122I transthyretin variant in elderly black AmericansC Cristina Quarta, Joel N Buxbaum, Amil M Shah, et al.
JACC. Heart Failure|March 16, 2020
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position PaperNasrien E Ibrahim, John C Burnett, Javed Butler, et al.
Diabetes Research and Clinical Practice|November 21, 2022
Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) studyMagnus O Wijkman, Brian L Claggett, Marcus V B Malachias, et al.
JACC. Heart Failure|December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health StatusSean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
JAMA Cardiology|October 10, 2019
Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities StudyStephen Y Wang, Andy S L Tan, Brian Claggett, et al.
European Journal of Heart Failure|September 19, 2018
The frailty syndrome and outcomes in the TOPCAT trialNatalie A Sanders, Mark A Supiano, Eldrin F Lewis, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|December 2, 2006
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic studyJens Jakob Thune, Lars Køber, Marc A Pfeffer, et al.
Pageof 122